Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.62 |
| ▸ | TNF | P01375 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.54 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisofylline SCHEMBL173236 | 1.00 | ADORA2B (0.62) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL6876106 | 1.00 | ADORA2B (0.62) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL6877251 | 0.95 | ADORA2B (0.57) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL6878645 | 0.93 | ADORA2B (0.65) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL6879511 | 0.93 | ADORA2B (0.65) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL6878616 | 0.93 | ADORA2B (0.65) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL173557 | 0.91 | ADORA2B (0.50) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL6876201 | 0.91 | ADORA2B (0.50) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL6876196 | 0.91 | ADORA2B (0.50) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL15423008 | 0.90 | ADORA2B (0.58) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444707-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118541360-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2024-08-23 | — | — | CN | claimed |
| CN-114728168-B | Triazole carbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2024-04-09 | — | — | CN | claimed |
| EP-4337641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4337654-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | claimed |
| CN-117295724-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-12-26 | — | — | CN | claimed |
| CN-117295717-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-12-26 | — | — | CN | claimed |
| WO-2023107938-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| EP-4161641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | claimed |
| CN-115942972-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-04-07 | — | — | CN | claimed |
| WO-2022240879-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022241023-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114728168-A | Triazolecarbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2022-07-08 | — | — | CN | claimed |
| US-20130324564-A1 | POLYMORPHS OF (S)-1-(4,4,6,6,6-PENTADEUTERO-5-HYDROXYHEXYL)-3-7-DIMETHYL-1H-PURINE-2,6(3H,7H)-DIONE | CONCERT PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | claimed |
| EP-2611807-A2 | POLYMORPHS OF (S)-1-(4,4,6,6,6-PENTADEUTERO-5-HYDROXYHEXYL)-3-7-DIMETHYL-1H-PURINE-2,6(3H,7H)DIONE | Concert Pharmaceuticals Inc. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031138-A9 | POLYMORPHS OF (S)-1-(4,4,6,6,6-PENTADEUTERO-5-HYDROXYHEXYL)-3-7-DIMETHYL-1H-PURINE-2,6(3H,7H)DIONE | CONCERT PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2012031138-A2 | POLYMORPHS OF (S)-1-(4,4,6,6,6-PENTADEUTERO-5-HYDROXYHEXYL)-3-7-DIMETHYL-1H-PURINE-2,6(3H,7H)DIONE | CONCERT PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324564-A1 | POLYMORPHS OF (S)-1-(4,4,6,6,6-PENTADEUTERO-5-HYDROXYHEXYL)-3-7-DIMETHYL-1H-PURINE-2,6(3H,7H)-DIONE | ADORA1, ADORA2A, ADORA3 | ADORA2B 9/4885TNF 3712/4885USP2 3922/4885 |
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | ADORA2B 459/4885TNF 2723/4885USP2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.